The addition of two Denosumab biosimilars to Amneal Pharmaceuticals' pipeline is a positive development for the company. This expansion of its oncology portfolio could potentially lead to increased revenues in the future, which would likely be viewed favorably by investors and could lead to an increase in the company's stock price in the short term.